Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base
- Oak Ridge, TN, March 11, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today announces the expansion of blood volume analysis (BVA) in three new hospitals through new analyzer purchases, and the utilization of Daxor's ezBVA Lab service. These new acquisitions further fuel BVA sales growth and underscore its clinical relevance.
- 03/11/2024
|
Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients
- Only Daxor's BVA Diagnostic Was Shown to Accurately Reflect Blood Volume Compared to Inferior Surrogates Oak Ridge, TN, March 08, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from Duke University Medical Center validating the benefits of blood volume analysis (BVA) in optimizing individualized therapy for heart failure patients with impaired renal function. Data were presented on 259 patients from three centers at the Technology and Heart Failure Therapeutics Conference (THT), which brought together the world's leading experts in heart failure innovations at the Westin Boston Seaport in Boston, Massachusetts March 4-6, 2024.
- 03/08/2024
|
Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference
- Oak Ridge, TN, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the Technology and Heart Failure Therapeutics Conference (THT), which brings together the world's leading experts in heart failure innovations at the Westin Boston Seaport in Boston, Massachusetts March 4-6, 2024.
- 02/26/2024
|
Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions
- Oak Ridge, TN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today announces two significant new customer transactions with Daxor's BVA-100™ (Blood Volume Analyzer) in January, marking a strong start to 2024.
- 02/12/2024
|
Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer
- The New BVA System is Designed to be Significantly Faster, Simpler and Give Results at the Bedside Oak Ridge, TN, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it has submitted its next-generation blood volume analyzer - Daxor BVA - to the U.S. Food and Drug Administration (FDA) via the 510(k)/CLIA-waiver dual submission pathway. Potential clearance is expected during the first half of 2024.
- 01/02/2024
|
New Randomized Controlled Trial Demonstrates the Efficacy of Daxor's BVA Guided-Care in Heart Failure Patients
- Data From Study Funded by NIH Presented at the American Heart Association Annual Meeting Oak Ridge, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the presentation of data from a Phase I National Institute of Health (NIH) sponsored randomized control trial (RCT) from two Veterans Affairs Medical Centers (Boston , Minneapolis), validating treatment decisions guided by the Company's BVA-100® diagnostic blood test benefitted patients with acute decompensated heart failure (ADHF). Data were presented at the American Heart Association Scientific Sessions 2023 at the Pennsylvania Convention Center in Philadelphia, PA on November 11, 2023.
- 11/13/2023
|
Expert Panelists Advocate Use of Daxor's Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting
- Leading Clinicians Highlight Significant Outcome Improvements with Daxor's Blood Volume Analysis Innovative Technology
- 10/13/2023
|
New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100® Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting
- Blood Volume Analysis (BVA) in 83-Patient Study Provided Highly Effective Guidance for Care of Heart Failure Patients Otherwise Unavailable Using Common Proxy Diagnostic Methods
- 10/11/2023
|
Daxor Corporation Awarded Support from the National Institutes of Health (NIH) Catalyze Preclinical Services Program
- Support for Development of Daxor's Non-Nuclear Tracer for Next Generation Blood Volume Analyzer Systems Aims to Deliver Gold Standard Accuracy with Increased Access, Ease of Use, and Frequency of Testing
- 10/04/2023
|
Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2023
- Daxor's Blood Volume Technology Featured at Scientific Session Oak Ridge, TN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces it will be attending the Annual Scientific Meeting of the Heart Failure Society of America (HFSA) which brings together the world's leading experts in heart failure at the Huntington Convention Center in Cleveland, Ohio from October 6-9, 2023.
- 09/27/2023
|
Daxor Corporation Awarded $305K Grant from the National Institutes of Health to Develop Blood Volume Guidance Software in Sepsis Patients
- Oak Ridge, TN, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Daxor C orporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced that the National Institutes of Health (NIH) National Institute of General Medical Sciences (NIGMS) has awarded the Company a $305K Phase I Small Business Innovative Research (SBIR) grant to support the development of the Sepsis FLO (Sepsis Fluid Optimizer), a clinical decision support tool designed to precisely guide blood volume management and treatment in sepsis patients.
- 09/11/2023
|
Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Oak Ridge, TN, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11 - 13, 2023 at the Lotte New York Palace.
- 09/07/2023
|
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
- Oak Ridge, TN, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today issued a corporate update in a Letter to Shareholders filed in its six-month shareholder report on Form N-CSR on August 28, 2023 from CEO and President, Michael Feldschuh.
- 08/28/2023
|
Daxor Corporation Reports a 20.64 Percent Increase in Diagnostic Test Kits Revenue From Prior Year Period in Form N-CSR Filing for the Six Months Ended June 30, 2023
- Net Assets Increases to $30.4 Million From $29.0 Million Oak Ridge, TN, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it filed Form N-CSR disclosing its schedule of portfolio holdings for the six-months ended June 30, 2023. The unaudited financials reported included an increase in revenue of 20.64 percent in the Company's diagnostic test kits compared to the same period from 2022 represents strong strides in the commercialization of its BVA-100® Blood Volume Analyzer through a combination of the purchase and leasing of capital equipment, the launch of Daxor's ezBVA Lab service, and the opening of eight new commercial and academic accounts during the past six- months.
- 08/28/2023
|
Daxor Corporation (DXR) Q4 2022 Earnings Call Transcript
- Daxor Corporation (NASDAQ:DXR ) Q4 2022 Results Conference Call March 2, 2023 9:00 AM ET Company Participants Scott Gordon - President, Core IR Michael Feldschuh - CEO Robert Michel - CFO Conference Call Participants Anthony Vendetti - Maxim Group Evan Greenberg - Legend Cap Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Daxor Corp. Fiscal Year 2022 Financial Results and Corporate Update Conference call.
- 03/06/2023
|
Daxor Corporation to Attend the H.C. Wainwright 24th Annual Global Investment Conference
- Oak Ridge, TN, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will attend the H.C. Wainwright 24th Annual Global Investment Conference being held on September 12 – 14, 2022 at the Lotte New York Palace.
- 09/06/2022
|
Daxor Corporation (DXR) Q2 2022 Earnings Call Transcript
- Daxor Corporation (NASDAQ:DXR ) Q2 2022 Earnings Conference Call August 25, 2022 4:30 PM ET Company Participants Scott Gordon - President and Co-Founder of CORE IR Michael Feldschuh - CEO & President Robert Michel - CFO Conference Call Participants Anthony Vendetti - Maxim Group Edward Wu - Ascendiant Capital Michael Samuels - Berthel Fisher Operator Good afternoon, and welcome to the Daxor Corporation First Half 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in listen-only mode.
- 08/26/2022
|
Daxor Corporation to Report First Half 2022 Financial Results on Thursday, August 25, 2022, and Provide Corporate Update
- Conference Call to be held on the same day at 4:30 p.m. Eastern Time
- 08/24/2022
|
Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Conference
- NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will present at the H.C. Wainwright Global Life Investment Hybrid Conference which is being held from May 23-26th at the Fontainebleau Miami Beach Hotel, Miami FL.
- 05/12/2022
|
Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
- Oak Ridge, TN, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh will present a corporate overview at the H.C. Wainwright BioConnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022.
- 01/06/2022
|
Daxor Corporation Receives $200K Matching Fund Award from Launch Tennessee
- The SBIR/STTR Matching Fund Grant Will Advance the Company's Innovation and Commercialization Efforts, and Job Creation
- 10/01/2021
|
Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting
- Data from Three New Studies and Two Ongoing Trials Presented at the Heart Failure Society of America Annual Scientific Meeting 2021 Data Highlight Importance of Blood Volume Analysis in Providing Appropriate, Personalized Care to Patients with Heart Failure
- 09/14/2021
|
Daxor Corporation to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
- Oak Ridge, TN, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Daxor Corpor a tion (NYSE:DXR), the global leader in blood volume measurement technology, today announces that President and Chief Executive Officer Michael Feldschuh will present at the 23rd Annual H.C. Wainwright Global Investment Conference which is being held virtually from September 13-15, 2021.
- 09/07/2021
|
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
- Oak Ridge, TN, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today it issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on form N-CSR on August 30, 2021, from CEO & President, Michael Feldschuh:
- 09/01/2021
|
Daxor Corporation Reports a 26.5 Percent Rise in Diagnostic Sales Revenue in Form N-CSR Filing for the Six Months Ended June 30, 2021
- Company forecasts further increase in sales driven by new distributor agreements
- 08/30/2021
|
Daxor's Blood Volume (BVA-100®) Diagnostic Demonstrates Clinical Utility In Critically-Ill COVID-19 Patients In Newly Published Data in Journal Critical Care
- Data Led to Multi-Center Study In Progress At Three Leading Hospitals
- 08/04/2021
|
Daxor Corporation to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021
- NEW YORK, May 28, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that Michael Feldschuh, Daxor's President and Chief Executive Officer will present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 2, 2021 at 4:30 PM ET.
- 05/28/2021
|
Daxor Corporation Announces 61% Increase in Q1 2021 Sales Revenue and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
- NEW YORK, NY, May 13, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced a Q1 2021 increase in revenue of 61% in its operating division on a year-over-year basis. In addition, the sales team has recorded the opening of five new customer accounts utilizing BVA and reports a growing pipeline of additional acquisitions of Daxor's BVA-100 Blood Volume Analyzer slated for Q3 2021 at major medical centers across the U.S.
- 05/13/2021
|
Newly Published Study Demonstrates Clinical Utility of Daxor's Blood Volume (BVA-100®) Diagnostic in the Assessment of Postural Tachycardia Syndrome (POTS)
- NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility of the BVA-100 blood test in postural tachycardia syndrome (POTS) published in the Journal of the American College of Cardiology from the Vanderbilt Autonomic Dysfunction Center in Nashville, TN.
- 04/29/2021
|
DAXOR CORPORATION ANNOUNCES NOVEL FLUORESCENT TRACER AND PHASE-TWO US AIR FORCE CONTRACT AWARD OF $750,000 FOR POINT-OF-CARE OPTICAL BLOOD VOLUME ANALYZER
- BREAKTHROUGH PATENT-PENDING TRACER DEVELOPED FOR BROAD USE
- 03/15/2021
|
Daxor Corporation Announces $0.48 Per Share NAV Increase and Files Annual Report for Fiscal 2020
- Revenues of Operating Division Increase by 50.4%
- 02/26/2021
|
DAXOR CORPORATION RECEIVES ISO 13485 QUALITY MANAGEMENT SYSTEM CERTIFICATION FOR THE BLOOD VOLUME ANALYZER (BVA-100®)
- Important Milestone for International Distribution
- 02/19/2021
|
DAXOR CORPORATION AWARDED GRANT FROM THE CENTER FOR ADVANCING POINT OF CARE TECHNOLOGIES (CAPCAT) TO DEVELOP A POINT-OF-CARE BLOOD VOLUME ANALYZER
- NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a grant from the Center for Advancing Point of Care Technologies (CAPCaT), a program run by the Massachusetts Medical Device Development Center (M2D2) funded by the National Heart, Lung, and Blood Institute and the National Center for Complementary and Integrative Health, both part of the National Institutes of Health (NIH), to develop a smart, point-of-care heart failure diagnostic for quantification of intravascular fluid overload to enable precision diuretic dosing.
- 02/05/2021
|
New Research Demonstrates the Clinical Utility with Daxor's Blood Volume Analyzer (BVA-100®) in Critical Care
- Study Presented At the Society for Critical Care Medicine (SCCM) 50th Congress
- 02/04/2021
|
Daxor to Present at the Inaugural H.C. Wainwright BioConnect 2021 Conference
- NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations), today announces that Michael Feldschuh, Daxor's President & Chief Executive Officer, will present at the inaugural H.C. Wainwright BioConnect Investment Conference which is being held from January 11th to 14th through a virtual format with on-demand video presentations.
- 01/08/2021
|
Daxor Corporation Announces Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
- NEW YORK, NY, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces additional acquisitions of Daxor's BVA-100® Blood Volume Analyzer at major medical centers across the U.S.
- 12/10/2020
|
Daxor Corporation to Present at the 13th Annual LD Micro Main Event 2020
- NEW YORK, NY, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor's President and Chief Executive Officer, will present at the virtual 2020 LD MicroCap Main Event on December 14, 2020 at 10:40 AM ET in Track One: Top Dollar.
- 12/09/2020
|
THIRD HOSPITAL JOINS MULTICENTER COVID-19 BVA-100® BLOOD TEST STUDY
- NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that Wake Forest Baptist Health will participate in an ongoing trial to treat patients hospitalized with COVID-19 utilizing Daxor's BVA-100 (Blood Volume Analyzer, "BVA") technology. Wake Forest School of Medicine is based in Winston-Salem, North Carolina, and is set to enroll patients under the leadership of Ashish K. Khanna, MD.
- 11/19/2020
|
OREGON HEALTH & SCIENCE UNIVERSITY JOINS MULTICENTER COVID-19 BVA-100® STUDY
- COVID-19 Investigation Continues at OHSU to Study Hospitalized Patients Utilizing Daxor's Blood Volume Analysis Technology
- 10/29/2020
|
New Data Released from the Mayo Clinic Utilizing Daxor’s BVA-100® Test Highlights Value of Daxor’s Diagnostic at the Heart Failure Society of America Virtual Annual Scientific Meeting 2020
- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume
- 10/02/2020
|
DAXOR ANNOUNCES COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH THE UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES
- NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has entered into a Cooperative Research and Development Agreement (“CRADA”) with The Uniformed Services University of the Health Sciences (“USU”), an institution of higher learning within the United States Department of Defense (DoD), and The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) on behalf of USU’s Battlefield Shock and Organ Support Research Program (BSOS). The partnership includes researching the effectiveness of Daxor’s BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. “Diagnostics currently used to guide battlefield resuscitation and transfusions, such as heart rate, cardiac output, stroke volume, and blood pressure, often misdiagnose the severity of volume derangement,” said Michael Feldschuh, CEO and President of Daxor. “Daxor’s BVA-100 Blood Volume Analysis (BVA) technology can greatly improve the existing standard of care by ensuring treatment decisions based on precise measurement of blood volume for better trauma survival outcomes.” Extensive peer-reviewed medical literature has validated Daxor’s BVA's enhancement of interventions through reliable and accurate blood volume measurement. Most relevant to military medicine is a prospective randomized controlled trial which demonstrated that, compared to standard care, actionable BVA-100 information changed surgical intensive care unit (SICU) fluid and red blood cell interventions by 44% of cases while reducing patient mortality by 66%. Additionally, it cut patients’ length of stay and days on a ventilator. The collaboration will encompass multiple projects with the ultimate objective of saving the lives of American soldiers and translating the results to civilian care. Target indications include hemorrhage, burn, trauma, sepsis and acute respiratory distress syndrome. “Collaborating with USU and HJF is an important milestone as we have been working on new technology and filed patent applications to extend the capabilities of our current FDA-cleared diagnostic system, the BVA-100, for both civilian and military use,” said Jonathan Feldschuh, Chief Scientific Officer at Daxor. “The results of this work will also support work on the next generation BVA device currently in development under a separate contract with the Department of Defense.”About Daxor CorporationDaxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information, please visit our website at Daxor.com.About HJFThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) is a global nonprofit organization with the mission to advance military medicine. HJF’s scientific, administrative and program operations services empower investigators, clinicians, and medical researchers around the world to make discoveries in all areas of medicine. With more than 35 years of experience, HJF serves as a trusted and responsive link between the military medical community, federal and private partners, and the millions of warfighters, veterans, and civilians who benefit from military medicine. For more information, visit hjf.org. Forward-Looking StatementsCertain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Investor Relations Contact: Bret Shapiro Sr. Managing Partner, CORE IR 516-222-2560 brets@coreir.com
- 08/04/2020
|
Daxor Corporation Announces Pricing of $7.0 Million Registered Direct Offering
- NEW YORK, July 20, 2020 -- Daxor Corporation (NYSE American: DXR) (“Daxor” or the “Company”), an investment company with innovative medical instrumentation and biotechnology.
- 07/20/2020
|
How Europe Kept Coronavirus Cases Low Even After Reopening
- Even as a surge in cases forces a number of U.S. states to reimpose restrictions, Europe’s reopening is for the most part going according to plan. Experts put that down to changing patterns of behavior and an understanding that this isn’t a “nothing crisis.”
- 07/20/2020
|
How Much Does Daxor's (NYSEMKT:DXR) CEO Make?
- Michael Feldschuh has been the CEO of Daxor Corporation (NYSEMKT:DXR) since 2016, and this article will examine the...
- 07/16/2020
|
DAXOR ANNOUNCES PROSPECTIVE RANDOMIZED CONTROL TRIAL AT DUKE UNIVERSITY MEDICAL CENTER TO GUIDE VOLUME TREATMENT IN HEART FAILURE PATIENTS
- Enrollment Commences Using the BVA-100® Diagnostic Blood Test NEW YORK, July 16, 2020 -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical.
- 07/16/2020
|
Daxor Announces Initiation of First-of-Its-Kind Multicenter BVA-100® Study in Hospitalized Patients With COVID-19
- COVID-19 Investigation Commences at NYU Langone Health with Daxor’s Blood Volume Analysis Technology NEW YORK, July 15, 2020 -- Daxor Corporation (NYSE MKT: DXR), an.
- 07/15/2020
|
Covid-19 : les Français attendent une relance verte
- Selon une étude BVA publiée par « Les Echos », les préoccupations de l'opinion n'ont pas été radicalement chamboulées par la crise sanitaire. Mais les valeurs de la famille, de la santé et de l'écologie ont regagné du terrain. La confiance dans les entreprises et les services publics est renforcée.
- 07/13/2020
|
DAXOR ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH AMERICAN MEDICAL DEPOT GOVERNMENT DISTRIBUTOR
- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, has signed a new distribution agreement with American Medical Depot “AMD,” one of the nation’s largest and diversified government healthcare distributors. As part of the agreement, the two parties are set to provide Daxor’s BVA-100 diagnostic blood test (Blood Volume Analysis) “BVA,” to government facilities across the United States, driving forward the use of BVA to help guide precise, individualized volume management in a wide variety of medical conditions including heart failure and COVID-19 related symptoms.
- 07/08/2020
|
Daxor Corporation Announces Appointment of Henry D. Cremisi, MD, FACP and Joy Goudie, Esq. to the Company’s Board of Directors
- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the appointments of Dr. Henry D. Cremisi and Joy Goudie, Esq. Ms. Goudie is replacing Berne Saxe, Esq.
- 06/30/2020
|
Postalis passa bem pela crise, enquanto busca ressarcimento por perdas do passado
- Fundo de pensão dos Correios consegue rentabilidade satisfatória em meio aos efeitos da pandemia, mas ainda carrega herança maldita de R$ 8,4 bilhões
- 06/28/2020
|
Killer whale submarine to be auctioned in the Netherlands
- A submarine that is a replica of a killer whale, and which can perform aerial stunts like those seen in the film Free Willy, is set to be auctioned in The Netherlands. According to local media reports, this unique marine vehicle reaches speeds of up to 62mph, can jump more than 16 feet into the air and travel 34mph underwater.
- 06/26/2020
|
Sub that looks like a killer whale and even LEAPS out of the water
- According to Dutch media, the two-person submarine reaches a top speed of 62 mph and can jump up to 16.4ft into the air. Underwater, the nifty vessel can hit speeds of 34 mph.
- 06/25/2020
|
Brexit warning: How Macron's 'biggest rival' has chilling plan for UK
- EMMANUEL MACRON's biggest rival in the 2022 French Presidential election, Edouard Philippe, has a chilling plan for post-Brexit Britain, which could see the City of London sidelined as the continent's banker, unearthed reports suggest.
- 06/24/2020
|
Municipales: à Paris, Buzyn veut "jouer le match"
- Une tournée médiatique tambour battant, une discrète campagne sur les pavés parisiens: Agnès Buzyn, candidate LREM arrivée troisième au premier tour des municipales à Paris, veut d'abord "jouer le match" avant de s'avouer vaincue, et met en garde contre un vote sanction "contre l'exécutif".
Mardi après-midi, c'est discrètement que la candidate de la macronie arrive dans les rues de l'hyper-centre, à deux pas de l'Hôtel de Ville
- 06/24/2020
|
Vacances d'été 2020: pourquoi Auvergne-Rhône-Alpes a la cote
- À l’heure des réservations pour cet été inédit, la région est l’une des destinations les plus prisées de l’Hexagone. Ses deux atouts ? Le Cantal et l'Ardèche.
- 06/23/2020
|
Oxford scientists could double dose of Covid-19 vaccine in jab hope
- In trials on pigs researchers found the vaccine being developed by scientists at Oxford appears to work better in a two-part 'prime' and 'boost' dosage - the same way the MMR jab is given.
- 06/23/2020
|
Covid-19 vaccines prove successful in pre-animal trial lab tests
- Two possible vaccines to tackle Covid-19 in animals have proved successful in laboratory tests, scientists at a University of Plymouth spinout company report.
- 06/23/2020
|
Baccalauréat : « Pourquoi il ne faut pas pérenniser le contrôle continu » «
- TRIBUNE. « Si le bac peut être obtenu à la faveur d’une notation de proximité, il n’est plus le bac », estime, dans une tribune au « Monde », l’historien et spécialiste de l’engagement enseignant Laurent Frajerman.
- 06/23/2020
|
Après le confinement, campagnes pour le dépistage de cancers
- 76% des Français déclarent qu'ils feront plus attention à leur santé à la suite de la crise du Covid-19: l'Institut national du cancer en profite pour lancer des campagnes de dépistage (cancers du sein et colorectal) et de prévention contre les excès de soleil.
Avant de se lancer dans ces opérations de prévention et de dépistage, l'INCa a voulu sonder l'état d'esprit de la population adulte
- 06/22/2020
|
Crise du Covid-19 : les fonctionnaires utiles et fiers de leur mission
- Pendant que la France se confinait, la plupart des agents de la Fonction publique ont continué à assurer leurs missions. Un engagement fort, qui a permis au pays de tenir le choc.
- 06/22/2020
|
Municipales à Paris : Hidalgo devance nettement Dati, selon un nouveau sondage
- Selon un dernier sondage BVA, la maire sortante recueille 45% des intentions de vote. Loin devant la candidate LR (34%) et la candidate LREM, Agnès Buzyn (18%).
- 06/22/2020
|
Municipales à Paris: Hidalgo plierait le match, Dati doublerait le score de Buzyn
- Selon notre étude exclusive BVA pour La Tribune et Europe 1, à une semaine du second tour des élections municipales, Anne Hidalgo bénéficierait d'une dynamique favorable, confortée par l'alliance avec EELV. Rachida Dati n'aurait pas pour autant dit son dernier mot, alors qu'Agnès Buzyn peinerait à capitaliser les électeurs de Cédric Villani. La Covid-19 et ses conséquences économiques et sociales figurent en tête des préoccupations des Parisiens.
- 06/22/2020
|
Macron Lags His Prime Minister in Popularity, Latest Poll Shows - BNN Bloomberg
|
Daxor Co. (NYSEAMERICAN:DXR) Short Interest Up 5.1% in June
- Daxor Co. (NYSEAMERICAN:DXR) saw a large growth in short interest in the month of June. As of June 15th, there was short interest totalling 29,000 shares, a growth of 5.1% from the May 31st total of 27,600 shares. Based on an average trading volume of 16,600 shares, the days-to-cover ratio is currently 1.7 days. Approximately […]
- 06/21/2020
|
Macron on brink: French PM Philippe’s popularity soars leaving President Macron lagging
- FRENCH Prime Minister Edouard Philippe's popularity has soared whilst President Emmanuel Macron continues to lag behind, a poll shows.
- 06/19/2020
|
How French PM's beard became symbol of coronavirus crisis
- TV viewers watched as Édouard Philippe’s white patch grew, along with his popularity
- 06/19/2020
|
Short Interest in Daxor Co. (NYSEAMERICAN:DXR) Increases By 5.1%
- Daxor Co. (NYSEAMERICAN:DXR) saw a significant growth in short interest during the month of May. As of May 29th, there was short interest totalling 29,000 shares, a growth of 5.1% from the May 14th total of 27,600 shares. Currently, 3.5% of the company’s stock are sold short. Based on an average daily volume of 16,600 […]
- 06/14/2020
|
Congés d'été : 20% de réservations pour l'étranger, contre 66% habituellement
|
Vacances d'été 2020: les Français plus attirés par la mer que par la campagne
- Une étude réalisée par les Entreprises du Voyage dévoile les intentions de départ en vacances des Français, à l’aube d’une saison estivale troublée par le coronavirus.
- 06/08/2020
|
Big Data : Saagie lève 25 millions pour accélérer en Europe et aux Etats-unis
- Editeur de logiciels et spécialiste du Big Data , Saagie a annoncé ce mardi 2 juin avoir finalisé une levée de fonds de 25 millions...
- 06/02/2020
|
Is Daxor Corporation (DXR) A Good Stock To Buy According To Hedge Funds?
- In this article you are going to find out whether hedge funds think Daxor Corporation (NYSE:DXR) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among […]
- 05/29/2020
|
Daxor Corporation, CEO Michael Feldschuh to Participate in Maxim Group’s COVID-19 Virtual Conference on May 27, 2020
- NEW YORK, May 26, 2020 -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume.
- 05/26/2020
|
Insomnie, anxiété : la santé mentale des Français s’est dégradée pendant le confinement
- EN UN GRAPHIQUE – Les indicateurs des autorités sanitaires sont supérieurs à ce qui est mesuré habituellement et font craindre un risque de « deuxième vague psychiatrique ».
- 05/26/2020
|
You'll need an EU pet passport to travel with your dog to Britain from next year
- That means an addition £60 per animal and each one will need rabies jabs
- 05/23/2020
|
INFOGRAPHIC: Q1-2020 | MOBILE MARKET MONITOR
- We release one Infographic in each quarter to summarize the handset and smartphone market activities in a single page.
- 05/22/2020
|
Daxor's BVA-100 Published in Novel Study in American Heart Association Journal - Circulation
|
Daxor’s BVA-100® Published in Novel Study in American Heart Association Journal - Circulation
- NEW YORK, May 22, 2020 -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume.
- 05/22/2020
|
Pets being abandoned over coronavirus fears fuelled by false claims animals can pass killer bug to humans
- PETS are being abandoned after false claims that animals can pass coronavirus to humans. Nearly two pets an hour are being abandoned in lockdown Britain, a shocking Sun Online investigation can rev…
- 05/07/2020
|
UPS AND DOWNS
- NEW YORK (AP) —The following list shows the NYSE MKT-listed stocks that have gone up the most and down the most based on percent of change for 2019. No securities trading below 1000 shares are included. Net and percentage change are the difference be- tween last year's closing price and this year's closing. Changes for issues added during the year are calcu- lated from closing prices on the first trading day. UPS . ... . . . . . . . . . . Name PE High Low Last Chg. Pct. 1 iBio 3.40 .21 1.12 + .87 + 349.8 2 AIM Immu rs 7.11 .51 2.08 + 1.54 + 282.4 3 AlphaPro 65 41.59 3.40 13.08 + 9.65 + 281.3 4 TakungArt 2.38 .40 1.55 + 1.05 + 210.6 5 NanoViricid 19.20 2.25 6.00 + 3.49 + 139.0 6 RetractblTch ..
- 04/30/2020
|
Daxor Wins $1.1M Contract From US Dept. Of Defense For Rapid Portable Blood Volume Analyzer
|
Daxor Awarded $1.1 Million Contract from United States Department of Defense (DOD) for Rapid Portable Blood Volume Analyzer
- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that the United States Department of Defense (DOD) has awarded the Company a $1.1 million contract for the development and deployment of a small, portable, highly accurate, battery-powered Blood Volume Analyzer. "The value of Blood Volume Measurement for improving outcomes is further validated by this important contract from the U.S. Military for our technology,” commented Daxor Corporation’s Chief Executive Officer Michael Feldschuh.
- 04/23/2020
|
Study finds cats and ferrets can catch coronavirus and a test is available
- Animal experts are learning that cats and ferrets may be more prone to low level infections than dogs and pet owners are being warned to be on their guard
- 04/09/2020
|
You CAN let your cat outside: Vet chiefs clarify pet owner guidance
- Cat owners should feel reassured that they can let their cats out of the house after all, following clarified guidance from the UK’s leading vet group. The British Veterinary Association (BVA) said it regretted “causing worry and upset amongst cat owners” after comments suggesting all cats should be kept inside.
- 04/08/2020
|
Vets confirm truth about cats spreading virus to Scots pet owners
- The British Veterinary Association has shared the updated guidance with vet practises across Scotland, urging owners to continue washing their hands.
- 04/08/2020
|
Cat lovers crash national vets' website after coronavirus fears
- Owners alarmed at prospect of lockdown for pets over concerns they may transmit Covid-19
- 04/08/2020
|
Some owners advised to keep cats inside during coronavirus crisis
- The British Veterinary Association says evidence suggests cats may be able to catch the virus from other cats.
- 04/08/2020
|
Cat warning: Pet owners urged to keep animals indoors during UK coronavirus lockdown
- THE coronavirus pandemic has prompted the British Veterinary Association to issue a warning urging Britons to keep their pet cats inside until the outbreak is under control.
- 04/08/2020
|
Should cats be kept indoors to prevent spread of coronavirus?
- There have been fears cats could help spread the virus
- 04/08/2020
|
105 Biggest Movers From Friday
- Gainers
Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares climbed 431% to close at $18.00 on Friday after the company reported that the FDA granted emergency expanded access...
- 03/23/2020
|
Biotech and hospitality stocks among premarket gainers
- Bellerophon Therapeutics (NASDAQ:BLPH) +472% on FDA nod for emergency use of INOpulse for Covid-19.Rand Capital (NASDAQ:RAND) +87% on its portfolio company developing automated test kits for detection
- 03/20/2020
|
Daxor Announces First Use OF BVA-100 To 'guide volume treatment in a patient infected with' The Coronvirus
|
Daxor Corporation’s BVA-100® Test Used to Guide Treatment In COVID-19 Patient
- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the first use of its BVA-100 test to guide volume treatment in a patient infected with the COVID-19 virus. The company also announced the release of a clinical protocol for fluid guidance when utilizing the BVA-100 diagnostic test for COVID-19 patients developed by leading medical experts. “Optimal volume management and knowledge of capillary status is key to survivability, preventing collapse of the circulatory system and allowing time to defeat infection,” said Michael Feldschuh, CEO of Daxor Corporation.
- 03/20/2020
|
Municipales : à Strasbourg, partie de poker menteur entre anciens camarades
- La République en marche espère une victoire d’Alain Fontanel, premier adjoint du maire (PS) Roland Ries, qui ne se représente pas. Ecologistes et socialistes sont en embuscade. Les probables alliances d’entre-deux-tours joueront un rôle majeur.
- 03/10/2020
|
Daxor Corporation Awarded Contract From US Air Force
|
Daxor Corporation Contracted to Adapt Its Blood Volume Analyzer Technology for U.S. Air Force Needs
- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that the U.S. Air Force (USAF) has awarded Daxor a contract to define specifications to adapt blood volume analysis technology to meet the needs of USAF. The selection was made under the USAF’s Small Business Innovative Research (SBIR) program.
- 03/09/2020
|
Daxor Corporation Announces Closing of $2.0 Million Registered Direct Offering Priced At-The-Market
- Daxor Corporation (NYSE American: DXR) (“Daxor” or the “Company”), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has closed its previously announced registered direct offering priced at-the-market of 140,352 shares of its common stock at a price of $14.25 per share, for aggregate gross proceeds of approximately $2.0 million. The Company intends to use the net proceeds for working capital and other general corporate purposes. Maxim Group LLC served as a financial advisor to Daxor in regards to the transaction.
- 03/06/2020
|
Strasbourg. LaREM marche sur des œufs dans la capitale alsacienne
- Dans une ville où les macronistes se montraient très confiants, la campagne de leur candidat, Alain Fontanel, se heurte à la dynamique autour de la liste EELV-PCF.
- 03/04/2020
|
3 Biotech Stocks Join the Coronavirus Fight
- With the number of global coronavirus infections now exceeding 93,000, Wall Street observers aren’t sure that monetary policy will be enough to limit an economic slowdown. Yesterday, the Federal Reserve cut US rates by 50 basis points, a level not seen since the 2008 economic crisis.Despite briefly rallying on the announcement, things took a turn, leaving bank stocks hit especially hard. The situation wasn’t helped by the fact that for the first time in history, the benchmark 10-year Treasury yield fell below 1%, although the yield was back above 1% by the end of the session.“The fact is, we’re coming into this crisis with far less ammunition globally. It’s not just Europe or Japan, even in China they have much less ammunition than the last time they had to launch a stimulus package,” J.P. Morgan Private Bank’s head of investment strategy Alex Wolf stated.As so much about COVID-19 remains unknown, it has become a race against the clock to find solutions. The CDC’s test for coronavirus was given emergency use authorization from the FDA, but there currently aren’t any vaccines or therapies available. Against this backdrop, 3 healthcare companies have sprung into action, hoping to develop an effective vaccine for the virus that has put the world on edge.Using TipRanks’ Stock Comparison tool, we were able to evaluate these 3 Buy-rated stocks alongside each other to get a sense of what the analyst community has to say. Here’s what we found out.Daxor Corporation (DXR)Daxor is a cutting-edge biotech company that specializes in blood volume measurement. Using its technology, it developed the first diagnostic blood test approved by the FDA for blood volume status and composition, called BVA-100 (Blood Volume Analyzer). Given that its BVA system could potentially be used to treat the coronavirus, it’s no wonder DXR shares are up 27% year-to-date while the broader market has fallen.These gains haven’t gone unnoticed by the pros on Wall Street. Maxim analyst Anthony Vendetti notes that DXR’s BVA technology was designed to help care for severely-ill patients experiencing blood volume imbalances caused by viral agents like the coronavirus. He points out that the company is reaching out to hospitals already using BVA devices to try and limit the number of deaths as the virus spreads in the U.S. On top of this, the biotech has a contract with the Department of Defense and finished its first Small Business Innovative Research (SBIR) program with the agency."We believe the company's BVA system can significantly improve the treatment of severely-ill patients with blood volume imbalances, such as those caused by viral agents (e.g., the coronavirus)," Vendetti noted.While Vendetti does acknowledge that its fourth quarter earnings results were somewhat disappointing, he thinks the print wasn’t all bad. DXR grew its test kit sales by 7% year-over-year, but it was hampered by supply-chain issues. The analyst argues that “if not for these supply-chain issues, DXR would have grown consumable kit sales at a much higher rate.”“Daxor signed up five new hospital centers in 2019, and received licensing for a central lab for BVA testing to facilitate work at hospitals that currently do not have its testing equipment on-site, opening up an additional source of revenue. Management anticipates several new product enhancements to the existing technology to be implemented in 2020, which we believe should improve product usability and increase BVA traction,” Vendetti added.In line with his optimistic take, the four-star analyst stayed with the bulls. Along with his Buy rating, Vendetti kept the $22 price target as is, suggesting 84% upside potential. (To watch Vendetti’s track record, click here)Judging from the consensus breakdown, it has been relatively quiet when it comes to other analyst activity. Over the last three months, only 2 analysts have reviewed Daxor. Both of which, however, were bullish, making the consensus a Moderate Buy. On top of this, the $21 average price target puts the upside potential at 75%. (See Daxor price targets and analyst ratings on TipRanks)Heat Biologics (HTBX)Thanks to its proprietary T-cell Activation Platform (TCAP), Heat Biologics has been able to develop therapies designed to stimulate a patient’s immune system to fight off cancer cells. Its two platforms, ImPACT and ComPACT, were created based on the heat shock protein, gp96, giving the company its name. Like Daxor, HTBX stock skyrocketed on Monday due to the technology’s potential use in the battle against coronavirus.According to Heat’s latest 8-K filing, it has submitted a provisional patent application for its immune system activating technology for the treatment or prevention of SARS-CoV-2 virus infection, which can cause the coronavirus. While no other details have been provided, Jason McCarthy of Maxim sees this development as a potential catalyst.“We do note that the gp96 immune therapy/ vaccine platform technology has been used in the past for developing viral targeting therapies including HIV, SIV and Zika (all preclinical). The key takeaway is that while gp96, which is the foundation of oncology programs IMPACT and COMPACT for Heat Biologics, may be applicable to viral diseases as well,” McCarthy commented.Part of what makes its technology ideal in targeting the coronavirus is the immunogenic properties of heat shock proteins. Specifically looking at gp96, the protein is unique in that it can target both the innate and adaptive immune system arms. This allows it to effectively target tumors, and in coronavirus’ case, pathogens.Based on all that Heat Biologics has going for it, McCarthy tells investors that his bullish thesis remains very much intact. It makes sense, then, that the analyst reiterated a Buy recommendation as well as his $1 price target. This conveys his confidence in HTBX’s ability to rise 67% over the next twelve months. (To watch McCarthy’s track record, click here)As McCarthy is the only analyst to offer up a take on this healthcare name, the consensus rating is a Moderate Buy. However, given its potential with respect to coronavirus, this could change very soon. (See HTBX stock analysis on TipRanks)Applied DNA Sciences (APDN)Last but certainly not least is Applied DNA Sciences, a company that uses biotech to provide security solutions. Having said that, it has found itself under the Street’s microscope after surging over 40% year-to-date on its DNA manufacturing technology’s possible use in a coronavirus vaccine candidate.On March 2, APDN broke the news of its collaboration with Takis Biotech, which has designed four experimental vaccines to target the coronavirus. Vendetti, who also covers this stock, tells clients that these candidates were created around the virus’ spike protein, a surface protein that plays a significant role in viral entry into host cells, and will be produced using linear PCR.Vendetti argues that several features of the approach, which involves targeting telomerase, could give APDN a leg up in the race to develop a vaccine.“This vaccine candidate has been shown in animal models of colorectal cancer to not only eliminate cancer cells, but prevent disease via prophylaxis, or 'vaccinating' against the cancer. As such, this is suggestive of immune memory using the APDN/Takis vaccine approach which could be beneficial if applied to COVID-19,” Vendetti said.Additionally, the analyst tells investors not to underestimate the importance of the linear DNA approach when it comes to developing an effective coronavirus vaccine. APDN’s linear PCR can target available virus sequences to quickly produce a vaccine. This is important as the coronavirus will most likely develop mutations as it replicates.Should this be the case, the vaccine could require a reformulation every year, and according to Vendetti, APDN is up for the challenge. “Given the speed at which the APDN platform generates linear DNA-based vaccines, APDN could alter the vaccine based on new strains very quickly, perhaps faster than anyone in the vaccine space, in our view,” he explained.To this end, Vendetti left both his Buy rating and $8 price target unchanged. At this target, the upside potential lands at 67%.Looking at the consensus breakdown, APDN follows the pattern established by the two other names on our list to a T. With only Vendetti’s call, the word on the Street is that APDN is a Moderate Buy. (See APDN price targets and analyst ratings on TipRanks)
- 03/04/2020
|
85 Biggest Movers From Yesterday
- Gainers
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) shares climbed 69.7% to close at $7.45. Inovio Pharmaceuticals announced an accelerated timeline Tuesday for the development of...
- 03/04/2020
|
Mid-Afternoon Market Update: Dow Tumbles 800 Points; Superconductor Technologies Shares Spike Higher
- Toward the end of trading Tuesday, the Dow traded down 3.03% to 25893.26 while the NASDAQ fell 3.13% to 8,672.22. The S&P also fell, dropping 2.87% to 3,001.43. Coronavirus...
- 03/03/2020
|
Mid-Day Market Update: Dow Falls Over 200 Points; Fed Issues Emergency Interest Rate Cut
- Midway through trading Tuesday, the Dow traded down 0.77% to 26497.47 while the NASDAQ fell 0.37% to 8,919.22. The S&P also fell, dropping 0.49% to 3,075.01. Coronavirus cases...
- 03/03/2020
|
50 Stocks Moving In Tuesday's Mid-Day Session
- Gainers
Superconductor Technologies Inc. (NASDAQ: SCON) shares jumped 107.1% to $0.4079. Superconductor Technologies and Allied Integral United announced a merger agreement....
- 03/03/2020
|
Mid-Morning Market Update: Markets Open Higher; Target Posts Mixed Q4 results
- Following the market opening Tuesday, the Dow traded up 0.27% to 26,774.19 while the NASDAQ rose 0.48% to 8,996.28. The S&P also rose, gaining 0.44% to 3,103.90. Coronavirus...
- 03/03/2020
|
Daxor Corporation Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market
- Daxor Corporation (NYSE American: DXR) (“Daxor” or the “Company”), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 140,352 shares of its common stock at a price of $14.25 per share, for aggregate gross proceeds of approximately $2.0 million, in a registered direct offering priced at-the-market. The Company intends to use the net proceeds for working capital and other general corporate purposes. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.
- 03/03/2020
|
108 Biggest Movers From Yesterday
|
Daxor Corporation Announces Engagement with Hospitals and Government for Use of the Blood Volume Analyzer (BVA-100®) to Stem COVID-19 Deaths
- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces active engagement with both hospitals and government agencies in the military and civilian sectors regarding the use of its technology to help guide fluid management of critically ill patients with COVID-19. The BVA-100 is the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms, and has been shown in a prospective randomized control trial to reduce mortality by as much as 66% in patient populations suffering predominantly from respiratory distress and septic shock.
- 03/02/2020
|
DAXOR CORPORATION ANNOUNCES RISE IN KIT SALES AND FILES FORM N-CSR FOR 2019
- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today filed a Form N-CSR disclosing its schedule of portfolio holdings as of December 31, 2019. For the third straight year on a double-digit pace, Daxor reported that kit sales rose over 7% year-on-year in the cardiology segment (22.7% excluding a supplier disruption in q4 of 2019), driven by increasing awareness of the value of blood volume analysis to improve heart failure outcomes through reduced mortality and readmissions, as well as five new hospital systems under contract. In addition, Daxor successfully completed its first SBIR with the DOD for the procurement of blood volume analyzers and looks forward to subsequent government contracts.
- 03/02/2020
|
55 Stocks Moving In Monday's Mid-Day Session
|
La bataille de l’apprentissage 2.0 : les tutos font la nique aux MOOC
- A l’heure de la digitalisation croissante de l’économie, l’éducation n’échappe pas au mouvement. L’enseignement en ligne à distance avec les MOOC semblaient avoir une longueur d’avance. Mais, moins académiques, les tutos sont bien plus populaires.
- 03/01/2020
|
Daxor says research demonstrates superiority of BVA-100 in critical care DXR
- Daxor says research demonstrates superiority of BVA-100 in critical care DXR
- 02/20/2020
|
New Research Further Demonstrates Clinical Superiority of Daxor Corporation’s Blood Volume Analyzer (BVA-100®) in Critical Care
- NEW YORK, Feb. 20, 2020 -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume.
- 02/20/2020
|
Daxor Corporation Highlights New Research Study Demonstrating 'Clinical Superiority' Of Co.'s Blood Volume Analyzer (BVA-100) In Critical Care
|
Daxor Corporation to Exhibit at the Society for Critical Care Medicine 49th Congress
- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be attending the Society for Critical Care Medicine (SCCM) 49th Congress at the Orlando Convention Center in Orlando, FL, from February 16-18th, 2019. Research from the University of Hawaii - John A. Burns School of Medicine relating to the use of Daxor’s BVA-100 (Blood Volume Analyzer) diagnostic test in critical care use is scheduled to be presented.
- 02/12/2020
|
New advice issued to dog owners as vomiting virus cases rise
- There have been nearly 500 cases of the virus which leaves dogs vomiting for days
- 02/10/2020
|
Here's What We Think About Daxor Corporation's (NYSEMKT:DXR) CEO Pay
- In 2016 Michael Feldschuh was appointed CEO of Daxor Corporation (NYSEMKT:DXR). First, this article will compare CEO...
- 12/31/2019
|
Novel Study from Yale University Utilizes Daxor’s Blood Volume Analyzer (BVA-100®) to Uncover Important Mechanism for Drug Empagliflozin
- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces new data from The Yale University School of Medicine that was presented on November 16th at the American Heart Association Scientific Sessions in Philadelphia, PA. Researchers at Yale utilized Daxor’s unique technology to analyze the volume shifts associated with the drug and were able to determine that there is a significant and sustained blood volume shift that is unique to this diuretic that may explain why diabetic HF patients have been shown in recent trials to benefit from its use.
- 11/21/2019
|
Daxor Highlights New Data From Yale University School Of Medicine Presented At American Heart Association Scientific Sessions
|
Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2019
- NEW YORK, Nov. 12, 2019 -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume.
- 11/12/2019
|
Read This Before Judging Daxor Corporation's (NYSEMKT:DXR) ROE
- One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- 10/29/2019
|
MicroCap Rodeo Investor Conference Lineup for October 15 and 16 - 2019
- AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16 th , 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, ...
- 10/15/2019
|
Daxor to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 1:30 PM Central Time
- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, announced that Michael Feldschuh, Chief Executive Officer of Daxor, will be a featured presenter at the inaugural MicroCap Rodeo Investor Conference in Austin, Texas at the Hilton Austin on Tuesday, October 15th at 1:30 PM (CT). Mr. Feldschuh will provide an overview of the Company’s business model and growth strategy and will be available for one-on-one meetings.
- 10/10/2019
|
Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100) Diagnostic in the Assessment of Hypertension
- NEW YORK, Sept. 24, 2019 -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood.
- 09/24/2019
|
MicroCap Rodeo Investor Conference - October 15 and 16, 2019, Austin Texas
- Company lineup is filling up fast with 50 good names in the microcap markets, as well as some great private and Pre-IPO companies AUSTIN, TX / ACCESSWIRE / September 19, 2019 / The MicroCap Rodeo's inaugural ...
- 09/19/2019
|
New Data Presented on Blood Volume at Annual Heart Failure Society Meeting Amid Call to Broadly Adopt Daxor’s Diagnostic Technology
- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces new data from the Mayo Clinic showing the benefits of the BVA technology in chronic heart failure patients. The study was presented on September 12th during the 23rd Annual Scientific Meeting of the Heart Failure Society of America (HFSA) at the Pennsylvania Convention Center in Philadelphia, PA. Dr. Wayne Miller of the Mayo Clinic in Rochester MN took part in an expert panel session focused on diagnostic measures to assess heart failure patients to determine optimal treatment strategies.
- 09/18/2019
|
Daxor Reports 38% Increase In BVA-100 Cardiology Kit Sales, Net Gain Of ~$498K For 6 Months
|
Daxor Reports Purchase Of BVA-100 Blood Volume Analyzer, No Terms Disclosed
|
Daxor shares are trading higher after Maxim Group initiated coverage on the stock with a Buy rating and announced a $22 price target.
|
HEATWAVE: Look after your small furries warns top vet - The Wokingham Paper
- PETS need extra care during the UK heatwave, warns the British Veterinary Association (BVA)
- 07/25/2019
|
Féminisation des instances dirigeantes : PME et ETI à la traîne
- Dans les comités de direction des PME et des ETI non cotées, la proportion de femmes oscille, suivant les secteurs, entre 18,5 % et 24,2 %,...
- 06/20/2019
|
Mode d'emploi du cerveau au boulot
- En augmentant la capacité des entreprises à prévoir le comportement de leurs collaborateurs et de leurs clients, les sciences cognitives bouleversent le monde du travail et du business. ,
Innovation,
- 06/03/2019
|
Companies Which Will Be Presenting At LD Micro's 9th Annual Micro Invitational Tues., Jun. 4, 2019
|
Daxor Highlights New Partnership With Leading Hospital In North Carolina To Integrate Co.'s BVA-100 Blood Volume Measurement Test As Part Of Standard Clinical Practice, No Terms Disclosed
|
Ascendiant Initiates Coverage On Daxor Corporation Common Stock with Buy Rating, Announces $20 Price Target
|
44 Biggest Movers From Yesterday
|
Shine Investment Advisory Services Inc Buys Daxor Corp, Apartment Investment & Management ...
|
UPDATE: Daxor Says Seeking Alpha Article Incorrectly Claimed Co.'s 'sole product is a blood volume analyzer called the BVA-100 but there does not appear to be any sales to date'
|
Daxor down 11% after corporate presentation
|
58 Biggest Movers From Yesterday
|
New Research Further Demonstrates Clinical Utility and Improved Ease of Use with Daxor Corporation's Blood Volume Analyzer (BVA-100®) in Critical Care
|
58 Biggest Movers From Yesterday
|
54 Biggest Movers From Yesterday
|
62 Biggest Movers From Yesterday
|
60 Biggest Movers From Friday
|
45 Stocks Moving In Friday's Mid-Day Session
|
62 Biggest Movers From Yesterday
|
51 Stocks Moving In Thursday's Mid-Day Session
|
Microcaps mostly among midday movers
|
56 Biggest Movers From Yesterday
|
44 Biggest Movers From Friday
|
Daxor Corporation Acquires BVA-100 Blood Volume Analyzer To Aspirus Wausau Hospital In Wisconsin
|
45 Stocks Moving In Wednesday's Mid-Day Session
|
64 Biggest Movers From Yesterday
|
45 Stocks Moving In Thursday's Mid-Day Session
|
55 Biggest Movers From Yesterday
|
Daxor up 13% premarket on positive data on blood volume analyzer
|
Daxor CFO Robert Michel Buys 2,500 @ Avg Price: $7.42
|
Daxor shares are trading higher after the company won a US Army contract.
|
Daxor Reports Strategic Collaboration With CHF Solutions To Manage Patients, Fluid Overload
|
10 Hottest Stocks From October 31, 2018
|
55 Stocks Moving In Tuesday's Mid-Day Session
|
Daxor Corporation Shares Resume Trade
|
Craze for designer pets is speeding up race toward unhealthy features
- The British Veterinary Association (BVA) is urging animal lovers to pick health over looks and not be lured into choosing such pets by social media.
- 10/25/2018
|
Daxor Names Robert Michel CFO
|
Daxor Reports Sale Of BVA-100 Kit Up 23% Year Over Year At Mid Year
|
41 Biggest Movers From Yesterday
|
28 Stocks Moving In Monday's Mid-Day Session
|
26 Stocks Moving In Wednesday's Pre-Market Session
|
48 Biggest Movers From Yesterday
|
Study Published In The Annals Of Thoracic Surgery Reveals Daxor's BVA-100 Device Unexpected Blood Loss Of 38% In Cardiac Surgical Patients Not Detected By Common Test In Use
|
41 Biggest Movers From Yesterday
|
34 Biggest Movers From Yesterday
|
24 Stocks Moving In Tuesday's Pre-Market Session
|
27 Stocks Moving In Wednesday's Mid-Day Session
|
36 Stocks Moving In Friday's Mid-Day Session
|
Daxor Corp. Shares Were Halted On Fourth Circuit Breaker Of The Session, This Time To The Downside; Shares At Afternoon Lows Upon Open, Still Up ~80% For The Session
|
Mid-Day Market Update: Dow Falls Over 1%; RF Industries Shares Spike Higher
|
Daxor Shares Up 17.6% Following New Critical Care Research Showing Benefit From BVA Use
|
28 Stocks Moving In Friday's Mid-Day Session
|
Think twice about buying 'squashed-faced' breeds, vets urge dog-lovers
- British Veterinary Association launches #breedtobreathe campaign to highlight serious health issues breeds such as pugs and French bulldogs are prone to
- 01/05/2018
|
Daxor Announces 300K Share Buyback
|
Daxor Corporation Provides Strategic Plan Update From Its June 27th Annual Meeting
|
Les cadres préfèrent le surprésentéisme à l’arrêt de travail
- Le chiffre est alarmant : 40% des salariés ont été arrêtés au moins une fois au cours de l’année 2016, un taux en hausse de 0,6 point par...
- 06/23/2017
|
Daxor Names John Wilkens CFO
|
Daxor Corporation Announces Delay in Filing of Form N-CSR for December 31, 2016
|
